



Innovating for
affordable healthcare

Shilpa Medicare Limited

Corporate & Admin Office:

“Shilpa House”, # 12-6-214/A-1, Hyderabad Road,
Raichur – 584 135, Karnataka, India
Tel: +91-8532-238704, Fax: +91-8532-238876
Email: info@vbshilpa.com, Web: www.vbshilpa.com
CIN: L85110KA1987PLC008739

Date: 23rd August 2022

Corporate Relationship Department
BSE Limited
Phiroze Jeejeebhoy Towers,
Dalal Street, Fort,
Mumbai – 400001

National Stock Exchange of India Limited
Exchange Plaza, 05th Floor,
Plot No: C/1, G Block,
Bandra Kurla Complex, Bandra (E)
Mumbai – 400051

Dear Sir / Madam,

Sub: Analysts/Investors Call

Ref: Stock Code: NSE: SHILPAMED/BSE-530549

Pursuant to Regulation 30(2) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we are enclosing herewith the schedule of Q1 FY23 Conference Call to be held on **Wednesday, August 24, 2022 at 03:45 PM IST.**

Thanking you,

Yours faithfully

For **SHILPA MEDICARE LIMITED**

RITU
TIWARY

Digitally signed
by RITU TIWARY
Date: 2022.08.23
16:55:32 +05'30'

Ritu Tiwary
Company Secretary & Compliance Officer



Innovating for
affordable healthcare

Shilpa Medicare Limited


Shilpa Medicare Limited's Q1 FY23 Conference Call on Wednesday, August 24, 2022 at 03:45 PM IST

Shilpa Medicare Limited will organize a conference call for investors and analysts on **Wednesday, August 24, 2022 at 03:45 PM IST.**

Senior Management team will represent the Company on the call.

The conference call will be initiated with a brief management discussion on the Q1 FY23 results, which were announced on August 11, 2022, followed by an interactive Question & Answer session.

Details of the conference call are as follows:

Time	:	03.45 PM IST on August 24, 2022
Local dial-in number	:	+91 22 6280 1141 +91 22 7115 8042
India local access number	:	+91 70456 71221 Available all over India
International Toll Free Numbers	:	Hong Kong - 800 964 448
	:	Singapore - 800 101 2045
	:	UK - 0 808 101 1573
	:	USA - 1 866 746 2133
Pre-Registration Link		 Click here to ExpressJoin the Call https://services.choruscall.in/DiamondPassRegistration/register?confirmationNumber=0985193&linkSecurityString=4868723f9
<i>Please dial-in 5 minutes prior to the scheduled start to ensure that you are connected to the call in time.</i>		

About Shilpa Medicare Limited:

Shilpa Medicare Limited (SML) started its operations as API manufacturer way back in 1989 at Raichur, Karnataka- India. Today Shilpa Medicare Limited is a global brand in manufacturing and supplying of affordable API and Formulation globally in different regulated markets.

Shilpa Medicare has been on path of expansion ever since its inception. With a regulatory recognized manufacturing set up and excellent scientific expert team in place, Shilpa Medicare has since been on a steady growth path. Currently they are one of the leaders in the Oncology market and offer a range of products spanning across APIs, Formulations both in terms of R&D and manufacturing capabilities. Further to consolidate the overall product offering, they are striving to put in efforts in field of novel drug delivery systems and biotech products along with widening their focus to other therapy areas. Where Shilpa Medicare Ltd is today is the result of their constant endeavours for more than three decades.

For further information please contact:

Dilip Kankani

Shilpa Medicare Limited

Tel: +91 8532 238704

Email: dilipkankani@vbsilpa.com**Siddharth Rangnekar / Mit Shah**

CDR India

Tel: ++91 22 6645 1209 / 1217

Email: siddharth@cdr-india.commit@cdr-india.com

DISCLAIMER:

Certain statements that may be made or discussed at the conference call may be forward-looking statements. Such forward-looking statements are subject to certain risks and uncertainties like significant changes in economic environment in India and overseas, tax laws, import duties, litigation, labour relations etc. Actual results might differ substantially from those expressed or implied. SH Kelkar Limited will not be in any way responsible for any action taken based on such statements and discussions; and undertakes no obligation to publicly update these forward-looking statements to reflect subsequent events or circumstances.